These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32454667)

  • 101. Enabling the drug combination of celecoxib through a spherical co-agglomeration strategy with controllable and stable drug content and good powder properties.
    Guo S; Yu C; Feng S; Wei J; Tong L; Li K; Gao Y; Zhao P; Li T; Chen M; Han D; Gong J
    Int J Pharm; 2022 Oct; 626():122180. PubMed ID: 36087627
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Increasing the Batch Size of a QESD Crystallization by Using a MSMPR Crystallizer.
    Hansen J; Kleinebudde P
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745799
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Afzelin induces immunogenic cell death against lung cancer by targeting NQO2.
    Xia L; Xu X; Li M; Zhang X; Cao F
    BMC Complement Med Ther; 2023 Oct; 23(1):381. PubMed ID: 37891619
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Particle design of naproxen-disintegrant agglomerates for direct compression by a crystallo-co-agglomeration technique.
    Maghsoodi M; Taghizadeh O; Martin GP; Nokhodchi A
    Int J Pharm; 2008 Mar; 351(1-2):45-54. PubMed ID: 17980983
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Formulation of cilostazol spherical agglomerates by crystallo-co-agglomeration technique and optimization using design of experimentation.
    Deshkar SS; Borde GR; Kale RN; Waghmare BA; Thomas AB
    Int J Pharm Investig; 2017; 7(4):164-173. PubMed ID: 29692975
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Preparation, evaluation and need of spherical crystallization in case of high speed direct tabletting.
    Pandey S; Patil AT
    Curr Drug Deliv; 2014; 11(2):179-90. PubMed ID: 23848355
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Spherical crystallization of drugs.
    Kovačič B; Vrečer F; Planinšek O
    Acta Pharm; 2012 Mar; 62(1):1-14. PubMed ID: 22472445
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Influence of excipients and processing conditions on the development of agglomerates of racecadotril by crystallo-co-agglomeration.
    Garala K; Patel J; Patel A; Raval M; Dharamsi A
    Int J Pharm Investig; 2012 Oct; 2(4):189-200. PubMed ID: 23580935
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Design and Development of Crystallo-co-agglomerates of Ritonavir for the Improvement of Physicochemical Properties.
    Mahajan NM; Malghade AD; Dumore NG; Thenge RR
    Turk J Pharm Sci; 2018 Dec; 15(3):248-255. PubMed ID: 32454667
    [TBL] [Abstract][Full Text] [Related]  

  • 111.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 112.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 6.